Login to Your Account

No radiation 'Galera' as $37M series B speeds oral mucositis drug

By Marie Powers
News Editor

Wednesday, October 14, 2015

Galera Therapeutics Inc. completed a $37 million series B designed to propel its pipeline of selective dismutase mimetics and move lead candidate, GC4419, into a randomized, double-blind phase IIb trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription